文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV感染者梅毒治疗后长期血清学结局:前瞻性队列研究

Long-Term Serologic Outcomes Following Treatment of Syphilis in People With HIV: A Prospective Cohort Study.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该前瞻性队列研究纳入184例首次诊断梅毒的HIV感染者,随访642人年,评估血清学应答率、时间、血清固定及血清转归。治疗后血清学应答中位时间6.53个月,12个月时84%应答,24个月累计89%应答;仅二期梅毒和较高最低CD4+计数与更快应答相关。

要点

  • HIV感染者梅毒治疗后12个月血清学应答率84%,24个月累计达89%。
  • 二期梅毒和较高最低CD4+计数与更快血清学应答独立相关。
  • 基线RPR较低与12个月应答失败相关,应答后51%呈血清固定。

核心结论

  • HIV感染者梅毒治疗后血清学应答时间、血清固定率及结局受非梅毒螺旋体试验滴度、梅毒分期和免疫状态共同影响。

研究设计与样本

  • 前瞻性队列研究,纳入184例首次诊断梅毒的HIV感染者,随访642人年。

主要发现

  • 治疗后血清学应答中位时间6.53个月(95% CI 6.055-7.012)。
  • Cox模型显示二期梅毒(HR 3.091,95% CI 1.330-11.440;P = .013)和较高最低CD4+计数(HR 1.002;95% CI 1.001-1.004;P = .043)与更快应答相关。
  • 12个月时155例(84%,95% CI 78%-89%)达到应答,较低基线RPR与失败相关(RR 0.972;95% CI .947-.997;P = .028)。
  • 应答后79例(51%)CD4+计数较高者呈血清固定,其中33例(46%)随访中转阴。
  • 29例无应答者中11例(38%)在更长随访(29.3个月,95% CI 23.03-35.7)后应答,4例中2例(14%)确诊神经梅毒,14例(48%)再感染;24个月时89%应答。

临床怎么用

  • 对HIV合并梅毒患者,应结合梅毒分期、基线RPR滴度和CD4+计数预判血清学应答速度与血清固定风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to evaluate the factors associated with rate and time to serological response, serofast status, and seroreversion in people with HIV (PWH) with a first diagnosis of syphilis. METHODS: The primary endpoint was serological response as determined by a 4-fold decline in rapid plasma regain (RPR) titer or seroreversion at 12 months. A secondary endpoint was cumulative serological response by 24 months of follow-up. Survival and multivariate analysis were used to compare different associated factors. RESULTS: A total of 184 PWH had a first syphilis episode in 642 person-years of follow-up. After treatment, the median time to serological response was 6.53 months (95% CI 6.055-7.012). In the Cox model, only secondary syphilis (HR 3.091, 95% CI 1.330-11.440; P = .013) and higher nadir CD4+ count (HR 1.002; 95% CI 1.001-1.004; P = .043) were associated with a faster response. At 12 months, 155 PWH (84%, 95% CI 78%-89%) achieved response and a lower baseline RPR (RR 0.972; 95% CI .947-.997; P = .028) was associated with failure. After response, 79 (51%) with higher CD4+ count remained as serofast status, and 33 of them (46%) seroreverted during follow-up. Of the 29 PWH without response, 11 (38%) reached serological response in a longer follow-up (29.3 months, 95% CI 23.03-35.7), and 2 out of 4 (14%) had confirmed neurosyphilis, whereas 14 (48%) had reinfections. Thus, 89% of PWH had serological response by 24 months. CONCLUSIONS: The time to serological response, the rate of serofast, and the outcome are the result of the interaction of nontreponemal test titers, syphilis stage, and the patient's immune status.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Casado JL, Vizcarra P, Izuzquiza I, et al. Long-Term Serologic Outcomes Following Treatment of Syphilis in People With HIV: A Prospective Cohort Study. Clin Infect Dis. 2026. PMID: 41846571. doi:10.1093/cid/ciag193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。